Idiopathic (or immune) thrombocytopenic purpura (ITP) is a relatively common hematologic condition, but one that the hematology community has failed to reach a consensus on with regard to treatment. In patients with chronic refractory ITP, there is even less agreement about treatment approaches, as this population represents a small, but challenging, fraction of the total cases of ITP. The aim of this article is to review the treatment options available for children with chronic refractory ITP, including a review of the benefits versus risks, rate of remission, and areas of ongoing and future research.
Blanchette, V., Freedman, J., & Garvey, B. (1998). Management of chronic immune thrombocytopenic purpura in children and adults. Seminars in Hematology, 35(1, Suppl. 1), 36-51.
2.
British Society for Haematology. (2003). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. British Journal of Haematology, 120, 574-596.
3.
Cines, D. B., Bussel, J. B., McMillan, R. B., & Zehnder, J. L. (2004). Congenital and acquired thrombocytopenia. American Society of Hematology, 390-406.
4.
Davis, P. W., Williams, D. A., & Shamberger, R. C. (1991). Immune thrombocytopenia: Surgical therapy and predictors of response. Journal of Pediatric Surgery, 26(4), 407-413.
5.
Fujimura, K., Takafuta, R., Kuriya, S. I., Abe, T., Akatsuka, J. I., Yasunaga, K., et al. (1996). Recombinant human Interferon α-2b (rh IFN α-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP). American Journal of Hematology, 51, 37-44.
6.
George, J. N. (2004a, July 28). Clinical manifestations and diagnosis of idiopathic thrombocytopenic purpura [Electronic version]. UpToDate, 12.3. Retrieved February 2, 2005, from http://www.utdol.com/application/topic/print.asp?file=platelet/5073
7.
George, J. N. (2004b, August 18). Treatment and prognosis of idiopathic thrombocytopenic purpura [Electronic version]. UpToDate, 12.3. Retrieved December 7, 2004, from http://www.utdol.com/application/topic/print.asp?file=platelet/5202
8.
George, J. N., Woolf, S. H., Raskob, G. E., Wasser, J. S., Aledort, L. M., Ballem, P. J., et al. (1996). Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88(1), 3-40.
9.
Imbach, P. (2003). Refractory idiopathic immune thrombocytopenic purpura in children: Current and future treatment options. Pediatric Drugs, 5(12), 795-801.
10.
Kuwana, M., Nomura, S., Fujimura, K., Nagasawa, T., Muto, Y., Kurata, Y., et al. (2004). Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood, 103(4), 1229-1236.
11.
Lanzkowsky, P. (1999). Disorders of platelets. In Pediatric hematology oncology (3rd ed., pp. 233-285). San Francisco, CA: Academic Press.
12.
Maloisel, F., Andres, E., Zimmer, J., Noel, E., Zamfir, A., Koumarianou, A., et al. (2004). Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long-term results. The American Journal of Medicine, 116, 590-594.
13.
McMinn, J. R., Cohen, S., Moore, J., Lilly, S., Parkhurst, J., Tarantino, M., et al. (2003). Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. American Journal of Hematology, 73, 135-140.
14.
Mocharnuk, R. S. (2003). Immune thrombocytopenia: Current understanding and future research. Medscape. Retrieved February 2, 2005, from http://www.medscape.com/viewarticle/459249?src=search
15.
Nathan, D. G., Ginsburg, D., Orkin, S. H., & Look, A. T. (2003). Acquired platelet defects. In C. J. Lantigua (Ed.), Hematology of infancy and childhood (6th ed., Vol. 2, pp. 1599-1609). Philadelphia, PA: W. B. Saunders.
16.
Nomura, S., Dan, K., Hotta, T., Fujimura, K., & Ikeda, Y. (2002). Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood, 100(2), 728-730.
17.
Nomura, S., Kuwana, M., & Ikeda, Y. (2003). Induction of T-cell tolerance in a patient with idiopathic thrombocytopenic purpura by single injection of humanized monoclonal antibody to CD40 ligand. Autoimmunity, 36(5), 317-319.
18.
Osterweil, N. (2004). Novel thrombopoietic protein effective, safe in ITP. Medscape. Retrieved February 2, 2005, from http://www.medscape.com/viewarticle/495548
19.
Pusiol, A., Cesaro, S., Nocerino, A., Picco, G., Zanesco, L., & Bisogno, G. (2004). Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. European Journal of Pediatrics, 163, 305-307.
20.
Roy-Byrne, P., Russo, J., Dugdale, D. C., Lessler, D., & Cowley, D. (2002). Rituximab: An anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. Journal of Southern Medical Journal, 95(10), 1209-1212. Retrieved from http://www.medscape.com/viewarticle/444919
21.
Schartz, J., & Bussel, J. B. (2004). Anti-CD40L: Biology and therapy in ITP. Blood, 104(4), 1178-1179.
22.
Waknine, Y. (2004). H. pylori eradication may increase platelet count in patients with chronic ITP. Medscape. Retrieved February 2, 2005, from http://www.medscape.com/viewarticle/490173
23.
Warren G Magnuson Clinical Center. (2004). Daclizumab to treat chronic immune thrombocytopenia. National Library of Medicine. Retrieved February 2, 2005, from http://clinicaltrials.gov/ct/show/NCT00049725?order=1
24.
Yetman, R. J. (2003). Evaluation and management of childhood idiopathic (immune) thrombocytopenia. Journal of Pediatric Health Care, 17(5), 261-263.
